Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

The US Food and Drug Administration (FDA) has granted traditional approval to Merck & Co’s (NYSE: MRK) Keytruda ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

On March 19, the Food and Drug Administration granted traditional approval to pembrolizumab, or Keytruda, marketed by Merck (MRK), with ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer ...

Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff ...

Actinium Pharmaceuticals (ATNM) announced a clinical program comprising of trials studying Actimab-A in combination with either Keytruda – ...

Merck, known for its prescription medicines, vaccines, and biologic therapies, has been a dominant force in oncology treatment, primarily due to the success of Keytruda. However, recent ...

Merck, known for its prescription medicines, vaccines, and biologic therapies, has been a dominant force in oncology treatment, primarily due to the success of Keytruda. However, recent developments ...